Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 5/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | CCND1 | P24385 | 9/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.40 |
| ▸ | CDK2 | P24941 | 9/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | JUN | P05412 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15298054 | 0.79 | MAPK8 (0.52) | MAPK8MAPK10MAPK9GSK3AGSK3B | |
| SCHEMBL18637985 | 0.79 | MAPK8 (0.52) | MAPK8MAPK10MAPK9GSK3AGSK3B | |
| SCHEMBL18638032 | 0.77 | MAPK8 (0.45) | MAPK8MAPK10MAPK9GSK3AGSK3B | |
| SCHEMBL17540002 | 0.72 | MAPK8 (0.52) | MAPK8MAPK10MAPK9GSK3AGSK3B | |
| SCHEMBL19042024 | 0.70 | RIPK2 (0.49) | MAPK8MAPK10MAPK9GSK3AGSK3B | |
| SCHEMBL18638030 | 0.70 | MAPK8 (0.45) | MAPK8MAPK10MAPK9GSK3AGSK3B | |
| SCHEMBL16074660 | 0.70 | MAPK8 (0.45) | MAPK8MAPK10MAPK9GSK3AGSK3B | |
| SCHEMBL7798583 | 0.70 | MAPK14 (0.62) | MAPK8MAPK10MAPK9MAPK14CCND1 | |
| SCHEMBL3305259 | 0.70 | MAPK14 (0.62) | MAPK8MAPK10MAPK9MAPK14CCND1 | |
| SCHEMBL18573360 | 0.70 | CDK4 (0.66) | CCND1CCNE1CDK2CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-10925878-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190070185-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | MAPK8 1583/4885MAPK10 1684/4885MAPK9 1698/4885 |
| US-10925878-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | MAPK8 1583/4885MAPK10 1684/4885MAPK9 1698/4885 |
| US-20190070185-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | MAPK8 1583/4885MAPK10 1684/4885MAPK9 1698/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | MAPK8 1583/4885MAPK10 1684/4885MAPK9 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.